Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17033307 | 0.82 | TLR8 (0.39) | CXCR3SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL17050167 | 0.81 | FBP1 (0.44) | MAPT | |
| SCHEMBL18649300 | 0.78 | CASR (0.40) | ALDH1A1MAPTRAB9ANPC1TP53 | |
| SCHEMBL17031843 | 0.78 | CA2 (0.35) | ALDH1A1MAPTTP53 | |
| SCHEMBL17040291 | 0.78 | TLR8 (0.45) | CXCR3SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL17561705 | 0.74 | CYP1A2 (0.49) | SMN1; SMN2ALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL7981680 | 0.66 | TLR8 (0.41) | CXCR3SMN1; SMN2ALDH1A1MAPTTP53 | |
| SCHEMBL6953638 | 0.62 | CXCR3 (0.56) | CXCR3SMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL21439371 | 0.62 | MCL1 (0.40) | SMN1; SMN2ALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL1942206 | 0.61 | PARP1 (0.45) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129407-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3110418-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CXCR3 4323/4885SMN1; SMN2 2468/4885ALDH1A1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.